Gene transfer to the airways of patients with cystic fibrosis (CF) could represent a treatment breakthrough. However, nineteen years after the identification of the CFTR gene, we still lack new therapies based on advancements in our understanding of the genetic basis of CF. While the principles of gene transfer are sound and have been demonstrated in cell culture and animal models, the promise of the approach has not yet been translated into "gene therapy" for CF. One reason for this delay has been the absence of an animal model that mimics the disease in which to test novel therapies. To overcome this bottleneck, the investigators of this PPG recently developed a new model of the disease by disrupting CFTR gene function in pigs, whose lungs resemble those of humans. This remarkable model exhibits features of CF in humans, including meconium ileus, pancreatic insufficiency, liver and gall bladder disease, and absence of CFTR anion transport in nasal and tracheal epithelia. Early signs in the longestlived animal suggest the spontaneous development of pulmonary inflammation and infection. In this Program, four senior and highly accomplished investigators will seize this unique opportunity and use CFTR-/- and CFTR AF508/AF508 pigs to study gene based therapies for lung disease. Project 1 focuses on the use of lentiviral vectors with envelopes that target the apical surface of epithelia to attain persistent expression of CFTR. They will develop an optimal lentiviral envelope for gene transfer to pig epithelia and test this in the CFTR AF508/AF508 model. Project 2 will use directed evolution of AAV vectors to develop more efficient AAV capsids for targeting the epithelial cells of the airways. They will then use these novel tools to transduce ain/vay epithelia and express CFTR with a goal of preventing or delaying the onset of pulmonary manifestations of CF in a pig model. Project 3 will continue to develop the CF pig model to address key issues including: correction of meconium ileus, the identification of modifier genes of the CF phenotype, and investigating the timing of CFTR expression needed to have a therapeutic effect. Project 4 will develop targeted RNA interference (RNAi) as a therapeutic tool for CF. Proof of principle studies will target the chemokine IL-8 using both viral and non-viral delivery approaches. The Project Leaders have an outstanding track record of collaboration in CF, and here they are focused on a common goal. Their research is highly creative and is supported by four cores that provide innovative services and key infrastructure. The discoveries from this PPG will accelerate the development of gene-based medicine for patients who suffer from this devastating disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL051670-19
Application #
8310195
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Banks-Schlegel, Susan P
Project Start
1997-09-01
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
19
Fiscal Year
2012
Total Cost
$2,268,494
Indirect Cost
$728,223
Name
University of Iowa
Department
Pediatrics
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Awadalla, Maged; Miyawaki, Shinjiro; Abou Alaiwa, Mahmoud H et al. (2014) Early airway structural changes in cystic fibrosis pigs as a determinant of particle distribution and deposition. Ann Biomed Eng 42:915-27
Gu, Xiaoling; Karp, Philip H; Brody, Steven L et al. (2014) Chemosensory functions for pulmonary neuroendocrine cells. Am J Respir Cell Mol Biol 50:637-46
Hoegger, Mark J; Fischer, Anthony J; McMenimen, James D et al. (2014) Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 345:818-22
Griffin, M A; Restrepo, M S; Abu-El-Haija, M et al. (2014) A novel gene delivery method transduces porcine pancreatic duct epithelial cells. Gene Ther 21:123-30
Krishnamurthy, Sateesh; Behlke, Mark A; Apicella, Michael A et al. (2014) Platelet Activating Factor Receptor Activation Improves siRNA Uptake and RNAi Responses in Well-differentiated Airway Epithelia. Mol Ther Nucleic Acids 3:e175
Abou Alaiwa, Mahmoud H; Beer, Alison M; Pezzulo, Alejandro A et al. (2014) Neonates with cystic fibrosis have a reduced nasal liquid pH; a small pilot study. J Cyst Fibros 13:373-7
Weldon, Sinéad; McNally, Paul; McAuley, Danny F et al. (2014) miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production. Am J Respir Crit Care Med 190:165-74
Hoegger, Mark J; Awadalla, Maged; Namati, Eman et al. (2014) Assessing mucociliary transport of single particles in vivo shows variable speed and preference for the ventral trachea in newborn pigs. Proc Natl Acad Sci U S A 111:2355-60
Berkebile, Abigail R; McCray Jr, Paul B (2014) Effects of airway surface liquid pH on host defense in cystic fibrosis. Int J Biochem Cell Biol 52:124-9
Gibson-Corley, K N; Olivier, A K; Meyerholz, D K (2013) Principles for Valid Histopathologic Scoring in Research. Vet Pathol :

Showing the most recent 10 out of 98 publications